Lineage Cell Therapeutics
LCTX
101 hedge funds and large institutions have $103M invested in Lineage Cell Therapeutics in 2022 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 18 increasing their positions, 24 reducing their positions, and 28 closing their positions.
1,476% more call options, than puts
Call options by funds: $268K | Put options by funds: $17K
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
4.64% less ownership
Funds ownership: 42.95% → 38.31% (-4.6%)
8% less funds holding
Funds holding: 110 → 101 (-9)
9% less capital invested
Capital invested by funds: $112M → $103M (-$9.71M)
25% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 24
29% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
+$3.19M |
| 2 |
Millennium Management
New York
|
+$1.11M |
| 3 |
RA
Raffles Associates
New York
|
+$823K |
| 4 |
E
Ergoteles
New York
|
+$730K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$501K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$7.98M |
| 2 |
State Street
Boston,
Massachusetts
|
-$2.2M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.35M |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$1.09M |
| 5 |
JP Morgan Chase
New York
|
-$782K |
LCTX Hedge Fund Activity: Q2 2022 in Review
101 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2022, worth a combined $103M — down 8.6% from $112M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of LCTX and 20 opened new positions — a net loss of 8 holders — while 24 trimmed existing stakes and 18 added.
The largest buyer was Laurion Capital Management, opening a new position worth an estimated $3.19M. The largest seller was BlackRock, cutting an estimated $7.98M.
- 101 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2022, down from 110 in Q1 2022.
- Funds reported $103M of Lineage Cell Therapeutics stock for Q2 2022, down 8.6% quarter-over-quarter.
- 20 funds opened new Lineage Cell Therapeutics positions in Q2 2022 and 28 closed out, a net change of -8 holders.
- The largest Lineage Cell Therapeutics buyer in Q2 2022 was Laurion Capital Management, an estimated $3.19M added.
- The largest Lineage Cell Therapeutics seller in Q2 2022 was BlackRock, an estimated $7.98M sold.
Based on aggregated 13F filings for Q2 2022.